InvestorsHub Logo
Followers 28
Posts 398
Boards Moderated 0
Alias Born 12/10/2015

Re: None

Tuesday, 10/23/2018 10:18:57 PM

Tuesday, October 23, 2018 10:18:57 PM

Post# of 457941
February 19-21, 2019, Anavex will be participating in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
From the event’s description:

Developed in combination with experts from Biogen, Eisai, Merck, AbbVie and other leading organizations, the meeting will cover:
• Research in novel therapeutic targets, beyond beta-amyloid and tau, to guide future research
• The challenges of preclinical models to improve neurodegenerative disease representation and clinical translation
• Identifying translatable biomarkers of neurodegeneration to better predict clinical efficacy


On 2/19, Daniel Klamer will be leading a pre-conference workshop:

Optimizing Precision Medicine for Neurodegenerative Diseases
Precision medicine utilizes biomarkers to deliver optimally targeted and timed interventions tailored to that individual’s molecular drivers of neurodegenerative disease. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are well-suited models for precision medicine due to the vast degree of individual variability. Precision medicine for these diseases is rapidly evolving due to fast expansion of the genetic, rapid biomarker development and greater opportunity for modifying treatments.
This workshop will help you to:
• Understand the integrated research platforms providing genetic analysis
• Discover the future for personal genome analysis
• Explore the genetics-based methods of drug discovery
• Assess the future for personalization of medical care


And on 2/21, he will be presenting:

The Use of Precision Medicine in Drug Development for Neurodegenerative Diseases
• Applying precision medicine to neurodegenerative disease therapeutics
• Evaluating the addition of new biomarkers to clinical trial and the use of biomarkers as endpoints
• Advancing discovery-phase neurodegenerative research products using genetics
• Identifying treatment response biomarkers from ANAVEX®2-73 clinical trials


Download the Event Guide here:
http://world-cns.com/about/full-event-guide/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News